152 related articles for article (PubMed ID: 23726804)
1. Plasma osteoprotegerin levels increase with the severity of cerebral artery atherosclerosis.
Kim J; Song TJ; Yang SH; Lee OH; Nam HS; Kim YD; Kim EH; Lee HS; Nam CM; Heo JH
Clin Biochem; 2013 Aug; 46(12):1036-1040. PubMed ID: 23726804
[TBL] [Abstract][Full Text] [Related]
2. Association of TRAIL and Its Receptors with Large-Artery Atherosclerotic Stroke.
Pan X; Pang M; Ma A; Wang K; Zhang Z; Zhong Q; Yang S
PLoS One; 2015; 10(9):e0136414. PubMed ID: 26334877
[TBL] [Abstract][Full Text] [Related]
3. Association of plasma osteoprotegerin levels with the severity of lower extremity arterial disease in patients with type 2 diabetes.
Niu Y; Zhang W; Yang Z; Li X; Wen J; Wang S; Zhang H; Wang X; Zhou H; Fang W; Qin L; Su Q
BMC Cardiovasc Disord; 2015 Aug; 15():86. PubMed ID: 26260869
[TBL] [Abstract][Full Text] [Related]
4. Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing-ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy.
Chang YH; Lin KD; He SR; Hsieh MC; Hsiao JY; Shin SJ
Metabolism; 2011 Aug; 60(8):1064-9. PubMed ID: 21251686
[TBL] [Abstract][Full Text] [Related]
5. Osteoprotegerin is Associated With Endothelial Function and Predicts Early Carotid Atherosclerosis in Patients With Coronary Artery Disease.
Morisawa T; Nakagomi A; Kohashi K; Kosugi M; Kusama Y; Atarashi H; Shimizu W
Int Heart J; 2015; 56(6):605-12. PubMed ID: 26549398
[TBL] [Abstract][Full Text] [Related]
6. Plasma osteoprotegerin level on admission is associated with no-reflow phenomenon after primary angioplasty and subsequent left ventricular remodeling in patients with acute ST-segment elevation myocardial infarction.
Erkol A; Oduncu V; Pala S; Kızılırmak F; Kılıcgedik A; Yılmaz F; Güler A; Karabay CY; Kırma C
Atherosclerosis; 2012 Mar; 221(1):254-9. PubMed ID: 22265272
[TBL] [Abstract][Full Text] [Related]
7. The value of serum osteoprotegerin levels in patients with angina like chest pain undergoing diagnostic coronary angiography.
Ghaffari S; Yaghoubi A; Baghernejad R; Sepehrvand N; Sokhanvar S; Haghjou AG
Cardiol J; 2013; 20(3):261-7. PubMed ID: 23788300
[TBL] [Abstract][Full Text] [Related]
8. Plasma levels of sRANKL and OPG are associated with atherogenic cytokines in patients with intermediate cardiovascular risk.
Raaz-Schrauder D; Schrauder MG; Stumpf C; Lewczuk P; Kilian T; Dietel B; Garlichs CD; Schlundt C; Achenbach S; Klinghammer L
Heart Vessels; 2017 Nov; 32(11):1304-1313. PubMed ID: 28567553
[TBL] [Abstract][Full Text] [Related]
9. Osteoprotegerin, trail and osteoprotegerin/trail ratio in patients at early phase of acute pancreatitis.
Dumnicka P; Zylka A; Kusnierz-Cabala B; Gurda-Duda A; Kuzniewski M; Drozdz R; Kulig J
Folia Med Cracov; 2014; 54(2):17-26. PubMed ID: 25648306
[TBL] [Abstract][Full Text] [Related]
10. Can osteoprotegerin be used to identify the presence and severity of coronary artery disease in different clinical settings?
Hosbond SE; Diederichsen AC; Saaby L; Rasmussen LM; Lambrechtsen J; Munkholm H; Sand NP; Gerke O; Poulsen TS; Mickley H
Atherosclerosis; 2014 Oct; 236(2):230-6. PubMed ID: 25104079
[TBL] [Abstract][Full Text] [Related]
11. Increased plasma osteoprotegerin levels are associated with the presence and severity of acute coronary syndrome.
Ren MY; Sui SJ; Zhang Y; Xu FY; Xu XQ; Zhao JJ; Du YM; Liu WH
Acta Cardiol; 2008 Oct; 63(5):615-22. PubMed ID: 19014006
[TBL] [Abstract][Full Text] [Related]
12. Osteoprotegerin and osteoprotegerin/TRAIL ratio are associated with cardiovascular dysfunction and mortality among patients with renal failure.
Kuźniewski M; Fedak D; Dumnicka P; Stępień E; Kuśnierz-Cabala B; Cwynar M; Sułowicz W
Adv Med Sci; 2016 Sep; 61(2):269-275. PubMed ID: 27128817
[TBL] [Abstract][Full Text] [Related]
13. Serum osteoprotegerin levels in patients with acute atherothrombotic stroke and lacunar infarct.
Guldiken B; Guldiken S; Turgut B; Turgut N; Demir M; Celik Y; Arikan E; Tugrul A
Thromb Res; 2007; 120(4):511-6. PubMed ID: 17258300
[TBL] [Abstract][Full Text] [Related]
14. Plasma osteoprotegerin levels are associated with the presence and burden of cerebral small vessel disease in patients with acute ischemic stroke.
Park MS; Chang Y; Kim KH; Park JH; Song TJ
Clin Neurol Neurosurg; 2021 Nov; 210():107010. PubMed ID: 34752988
[TBL] [Abstract][Full Text] [Related]
15. Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein.
Rhee EJ; Lee WY; Kim SY; Kim BJ; Sung KC; Kim BS; Kang JH; Oh KW; Oh ES; Baek KH; Kang MI; Woo HY; Park HS; Kim SW; Lee MH; Park JR
Clin Sci (Lond); 2005 Mar; 108(3):237-43. PubMed ID: 15569000
[TBL] [Abstract][Full Text] [Related]
16. Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor κB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis.
Giaginis C; Papadopouli A; Zira A; Katsargyris A; Klonaris C; Theocharis S
Med Sci Monit; 2012 Oct; 18(10):CR597-604. PubMed ID: 23018352
[TBL] [Abstract][Full Text] [Related]
17. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
[TBL] [Abstract][Full Text] [Related]
18. Comparison of osteoprotegerin to traditional atherosclerotic risk factors and high-sensitivity C-reactive protein for diagnosis of atherosclerosis.
Mogelvang R; Pedersen SH; Flyvbjerg A; Bjerre M; Iversen AZ; Galatius S; Frystyk J; Jensen JS
Am J Cardiol; 2012 Feb; 109(4):515-20. PubMed ID: 22100028
[TBL] [Abstract][Full Text] [Related]
19. Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as prognostic factors in rheumatoid arthritis: results from the ESPOIR cohort.
Audo R; Daien C; Papon L; Lukas C; Vittecoq O; Hahne M; Combe B; Morel J
Arthritis Res Ther; 2015 Jul; 17(1):193. PubMed ID: 26220665
[TBL] [Abstract][Full Text] [Related]
20. Below-knee arterial calcification in type 2 diabetes: association with receptor activator of nuclear factor κB ligand, osteoprotegerin, and neuropathy.
Bourron O; Aubert CE; Liabeuf S; Cluzel P; Lajat-Kiss F; Dadon M; Komajda M; Mentaverri R; Brazier M; Pierucci A; Morel F; Jacqueminet S; Massy ZA; Hartemann A
J Clin Endocrinol Metab; 2014 Nov; 99(11):4250-8. PubMed ID: 25013993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
